OakChart

Aethlon Medical Inc

AEMDHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 9:22 AM ET

5.550.00 (0.00%)
2026-11-11 15:23 CET
Market cap
8.90 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-6.94 USD m
Free cash flow, TTM
-7.19 USD m
EPS diluted, TTM
-40.99
P/E
-
Compare

Price

AEMD against its 20, 50 and 200-day averages
2050200beatmiss
0.0010.0020.0046.3M92.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AEMDclose 5.5520-day 5.3650-day 4.98200-day 7.425.55

80.5% under 28.45 on 30 Oct 2025. Last 15 sessions, 23.0% high to low

Profile

AEMD
52-week range, 17% of the way up
1.4125.66

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce on April 17, 1991 and is headquartered in San Diego, CA.

Employees9
IPOMay 11, 1994
Beta1.22
ATR, 14d0.37
Rel volume0.00
Short float2.90%
Insider own6.98%
Inst own7.39%

Snapshot

6 groups

Valuation

Index-
Market Cap8.90M
Enterprise Value4.34M
Income-6.94M
Sales0.00M
Book/sh10.89
Cash/sh3.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees9
IPOMay 11, 1994

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.51
P/C1.81
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.04
Current Ratio5.04
Debt/Eq0.07
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-40.99
EPS next Y-1.91
EPS next Q-2.70
EPS this Y87.76%
EPS next Y70.59%
EPS next 5Y76.48%
EPS past 3/5Y71.71% 54.12%
Sales past 3/5Y- -
EPS Y/Y TTM87.54%
Sales Y/Y TTM-
EPS Q/Q90.52%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.-2.42% -

Ownership

Insider Own6.98%
Insider Trans0.00%
Inst Own7.39%
Inst Trans5.87%
ROA-120.22%
ROE-160.91%
ROIC-133.43%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.60%
SMA5011.37%
SMA200-25.19%
Trades-

Technical

Shs Outstand1.60M
Shs Float1.49M
Short Float2.90%
Short Ratio0.02
Short Interest0.04M
52W High25.66 -78.37%
52W Low1.41 293.62%
Volatility4.78% 7.18%
ATR (14)0.37
RSI (14)53.71
Beta1.22
Rel Volume0.00
Avg Volume2.52M
Volume129

Performance

Perf Week-3.48%
Perf Month-0.54%
Perf Quarter89.42%
Perf Half Y-48.13%
Perf YTD-59.93%
Perf Year-74.42%
Perf 3Y-99.19%
Perf 5Y-99.95%
Perf 10Y-100.00%
Recom3.00
Target Price13.25
Prev Close5.55
Price5.55
Change %0.00%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jul 07, 2025ResumedHH.C. WainwrightNeutral$1.50-73.0%

Peers

Mkt cap
TickerCompanyMkt cap
CTSOCytosorbents Corp18.28M
ICUSeaStar Medical Holding Corp10.31M
CERSCerus Corp403.91M
NUWENuwellis Inc2.77M
OMOutset Medical Inc79.55M
VNRXVolitionRX Ltd5.32M
HAEHaemonetics Corp5.49B
NEPHNephros Inc34.24M
RMTIRockwell Medical Inc29.46M
DXRDaxor Corp49.82M

News

latest 14 of 200
  • Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Aethlon Medical Shares Surge Over 400% After Announcing North Immunology Merger (InvestorsHub) +374.13%
  • North Immunology joins biotech reverse merger boom with Aethlon deal (BioPharma Dive)
  • Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis (PR Newswire)
  • Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier Program (PR Newswire)
  • Loading…
  • Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026 (PR Newswire) -7.67%
  • Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier (PR Newswire) -5.51%
  • Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules (PR Newswire) +11.25%
  • Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier (PR Newswire)
  • From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak (Newsfile)
  • Aethlon Medical advances Hemopurifier study as final trial cohort nears completion (Proactive)
  • Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
  • Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update (PR Newswire) -5.94%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-08-13-4.020-3.925-4.0200.000.002
2025Q42026-06-1020.400-10.828-5.9990.000.003
2025Q32026-02-12-12.250-13.750-12.2600.000.001
2025Q22025-11-12-18.700-18.317-18.7050.000.003
2025Q12025-08-13-42.500-43.047-42.4260.000.003
2024Q42025-06-26-161-53.665-155.780.000.003
2024Q32025-02-12-52.000-81.335-50.2720.000.003
2024Q22024-11-13-80.000-78.000-80.5600.000.002
2024Q12024-08-14-136-126-137.920.000.002
2023Q42024-06-27-348-492-368.920.000.003
2023Q32024-02-14-548-540-550.940.000.002
2023Q22023-11-14-488-560-488.720.000.003
2023Q12023-08-10-560-520-539.960.000.002
2022Q42023-06-28-400-580-429.160.570.002
2022Q32023-02-13-480-320-496.760.004.763
2022Q22022-11-14-720-746.8-734.120.570.073

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-7,480-13,480-7,4660.650.73
2020FY-2,600-2,730-2,6090.660.99
2021FY-2,840-2,387-2,8230.291.01
2022FY-2,360-2,520-2,3430.570.00
2023FY-1,944-2,075-1,9430.000.00
2024FY-429-291.33-428.880.000.00
2025FY-53.050-51.033-53.0500.000.00
2026FY--6.493--0.00
2027FY--1.910--0.00
2028FY--0.690---
2029FY--0.220--8.87
2030FY-0.070--24.03

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2026-08-172000.000.000.00
2026Q2S2026-08-141000.000.000.00
2026Q2S2026-08-131000.000.000.00
2026Q2S2026-06-111000.000.000.00
2026Q2S2026-02-131000.000.000.00
2026Q2S2025-11-131000.000.000.00
2026Q2S2025-11-111000.000.000.00
2026Q2S2025-11-101000.000.000.00
2026Q2S2025-11-091000.000.000.00
2026Q2S2025-11-081000.000.000.00
2026Q2S2025-11-071000.000.000.00
2026Q2S2025-11-061000.000.000.00
2026Q2S2025-11-051000.000.000.00
2026Q2S2025-11-041000.000.000.00

Estimate history

EPS, annual-27600-20506.8-7466.16-2609.16-2823.36-2343-1943.376-428.876-53.057-40.9874
Period201720182019202020212022202320242025TTM
EPS, quarterly-137.916-80.56-50.272-155.776-42.426-18.705-12.26-5.999-4.024
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual0.150.230.650.6590.2940.5740000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual000.0020.0030.0040.0060.0070.040.3140.477
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0350.0350.0350.040.0520.1520.1950.3140.477
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.570.290.660.650.23
Cost of Goods Sold Incl. D&A0.540.320.340.360.270.15---
Gross Profit-0.54-0.32-0.34-0.360.310.14---
Selling, General and Administrative Excl. Other6.546.979.0012.2812.2110.568.516.556.20
Research and Development1.971.912.212.522.752.342.070.930.90
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.08-7.29-9.34-12.64-11.90-10.42-7.89-5.93-6.00
Interest Expense-0.010.010.00-0.000.000.050.22
Unusual Expense0.000.004.610.000.000.000.000.450.00
Net Income Before Taxes-6.94-7.15-13.39-12.21-12.03-10.42-7.89-6.38-6.22
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-6.94-7.15-13.39-12.21-12.03-10.42-7.89-6.38-6.22
Net Income From Continuing Operations-6.94-7.15-13.39-12.21-12.03-10.42-7.89-6.37-6.19
Net Income-6.94-7.15-13.39-12.21-12.03-10.42-7.89-6.37-6.19
EPS (Recurring)-18.03-53.06-325.44-1,943.38-2,343.00-2,823.37-2,609.14-7,099.65-20,506.99
EPS (Basic, Before Extraordinaries)-40.99-53.06-428.88-1,943.38-2,343.00-2,823.36-2,609.16-7,466.16-20,506.80
EPS (Diluted)-40.99-53.06-428.88-1,943.38-2,343.00-2,823.36-2,609.16-7,466.16-20,506.80
EBITDA-6.54-6.97-9.00-12.28-11.63-10.27-7.85-5.90-5.97
Non-Operating Income (Expense)0.160.160.580.43-0.130.000.000.050.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.250.280.421.221.050.750.780.841.32
Price To Sales Ratio----13.6873.2437.247.9874.99
Gross Margin----53.8047.57---
Operating Margin-----2,072.05-3,542.53-1,197.07-912.04-2,612.53
Net Margin-----2,094.89-3,540.90-1,196.58-980.33-2,697.75
Shares Outstanding0.480.310.040.010.010.000.000.000.00
Market Capitalization8.908.905.754.368.7922.5124.6714.2417.65

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.080.160.150.150.080.080.23
Gross Profit-0.15-0.08-0.16-0.15-0.15-0.08-0.08-0.23
Selling, General and Administrative Excl. Other1.431.851.911.361.641.921.732.68
Research and Development0.550.590.530.290.521.330.240.26
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.58-1.93-2.06-1.51-1.79-2.00-1.81-2.90
Interest Expense-0.01---0.010.000.00
Unusual Expense0.000.000.000.000.004.610.000.00
Net Income Before Taxes-1.55-1.88-2.02-1.49-1.76-6.25-1.75-2.81
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.55-1.88-2.02-1.49-1.76-6.25-1.75-2.81
Net Income From Continuing Operations-1.55-1.88-2.02-1.49-1.76-6.25-1.75-2.81
Net Income-1.55-1.88-2.02-1.49-1.76-6.25-1.75-2.81
EPS (Recurring)-4.02-6.00-12.26-18.71-42.43-75.36-50.27-80.56
EPS (Basic, Before Extraordinaries)-4.02-6.00-12.26-18.70-42.43-155.78-50.27-80.56
EPS (Diluted)-4.02-6.00-12.26-18.70-42.43-155.78-50.27-80.56
EBITDA-1.43-1.85-1.91-1.36-1.64-1.92-1.73-2.68
Non-Operating Income (Expense)0.030.060.040.020.030.370.060.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.040.060.070.070.070.070.090.11
Shares Outstanding0.480.310.190.150.050.040.030.03
Market Capitalization8.903.442.705.703.125.7512.036.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.035.505.4414.5317.079.869.603.836.97
Short Term Receivables0.000.000.000.000.130.150.210.000.07
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.330.450.510.560.960.340.230.210.18
Total Current Assets5.365.955.9515.0918.1610.3510.044.047.23
Net Property, Plant & Equipment0.661.281.902.301.140.200.280.010.03
Total Investments and Advances0.100.100.090.090.090.050.000.000.00
Intangible Assets0.000.000.000.000.000.060.060.070.08
Deferred Tax Assets--------0.00
Other Assets0.210.030.310.030.030.010.010.010.02
Total Assets6.337.368.2517.5119.4210.6710.394.127.35
Short Term Debt Incl. Current Port. of LT Debt0.510.490.290.270.130.040.100.960.00
Accounts Payable0.380.530.780.430.500.340.290.130.12
Other Current Liabilities0.550.870.760.801.201.000.680.730.35
Total Current Liabilities1.451.901.831.511.821.381.071.820.48
Long Term Debt0.000.340.650.940.600.000.040.000.84
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities--------0.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities1.452.242.482.442.431.381.111.821.32
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4.895.125.7715.0617.139.439.412.436.13
Total Shareholders Equity4.895.125.7715.0617.139.439.412.436.13
Accumulated Minority Interest0.000.000.000.00-0.14-0.14-0.13-0.13-0.10
Total Equity4.895.125.7715.0616.999.299.282.306.03
Total Liabilities & Stockholders Equity6.337.368.2517.5119.4210.6710.394.127.35
Book Value Per Share15.56127.60877.102,620.724,444.633,104.574,018.107,656.5320,747.04
Tangible Book Value Per Share15.56127.59876.932,620.434,444.063,085.823,993.547,446.0420,490.56
Full-Time Employees9914151410866
Price to Book Ratio0.511.120.570.581.312.621.515.363.89
Return on Assets-104.46-171.58-94.80-65.15-69.24-74.91-87.85-107.97-125.12
Return on Equity-142.89-245.88-117.21-74.73-78.42-83.72-107.72-144.75-166.79
Return on Invested Capital-146.36-245.19-190.27-75.17-58.73-83.63-67.43-255.44-81.43
Quick Ratio3.703.133.2510.039.957.539.402.2115.13
Current Ratio3.703.133.2510.039.957.539.402.2115.13

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-6.94-7.15-13.39-12.21-12.03-10.42-7.89-6.38-6.22
Depreciation0.320.320.340.360.270.150.040.030.03
Other Funds (Non Cash)0.550.575.311.241.190.750.781.271.46
Funds from Operations-6.07-6.26-7.74-10.61-10.57-9.52-7.07-5.08-4.73
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.11-0.740.090.480.07-0.250.31-0.120.44
Cash from Operating Activities-7.18-7.00-7.65-10.13-10.51-9.77-6.76-5.20-4.29
Capital Expenditures-0.01-0.000.00-0.25-0.94-0.35-0.06-0.150.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.000.00-0.25-0.94-0.35-0.06-0.150.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.486.667.911.328.9317.467.2612.161.15
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.19
Sale of Common Pref Stock8.486.667.911.328.9317.467.2612.161.34
Proceedsfrom Stock Options5.735.813.541.328.9317.467.2612.161.34
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.990.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.14-0.14-0.18-0.03-0.01-0.09-0.13-0.040.00
Other Financing Activities Uses-0.14-0.14-0.18-0.03-0.01-0.09-0.13-0.040.00
Cash from Financing Activities8.346.527.731.298.9117.377.1311.131.15
Exchange Rate Effect0.020.01-0.010.00-0.01----
Net Change in Cash1.17-0.470.07-9.09-2.547.250.305.78-3.15
Free Cash Flow-7.19-7.00-7.65-10.38-11.45-10.12-6.82-5.35-4.29
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments4.935.036.965.853.775.50
Short Term Receivables0.000.000.000.220.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.280.330.190.180.280.45
Total Current Assets5.225.367.146.254.045.95
Net Property, Plant & Equipment0.530.660.820.971.121.28
Total Investments and Advances0.100.100.100.100.100.10
Intangible Assets0.000.000.000.000.000.00
Other Assets0.390.210.000.000.040.03
Total Assets6.246.338.067.325.317.36
Short Term Debt Incl. Current Port. of LT Debt0.370.510.330.370.430.49
Accounts Payable0.410.380.470.570.570.53
Other Current Liabilities0.260.550.460.460.620.87
Total Current Liabilities1.041.451.261.401.631.90
Long Term Debt0.000.000.090.170.260.34
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.041.451.341.581.882.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.204.896.715.753.425.12
Total Shareholders Equity5.204.896.715.753.425.12
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.204.896.715.753.425.12
Total Liabilities & Stockholders Equity6.246.338.067.325.317.36
Book Value Per Share10.8915.5634.4937.7465.87127.60
Tangible Book Value Per Share10.8915.5634.4937.7465.86127.59
Full-Time Employees-9---9
Price to Book Ratio0.510.700.400.990.911.12
Return on Assets-120.22-104.46-158.03-139.25-150.45-171.58
Return on Equity-160.91-142.89-208.60-191.39-207.29-245.88
Return on Invested Capital-29.77-38.56-29.68-25.13-47.90-114.55
Quick Ratio5.043.705.684.452.483.13
Current Ratio5.043.705.684.452.483.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-1.55-1.88-2.02-1.49-1.76-6.25
Depreciation0.15-0.140.160.150.15-0.13
Other Funds (Non Cash)0.050.360.070.070.074.97
Funds from Operations-1.35-1.67-1.79-1.26-1.53-1.41
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.55-0.08-0.08-0.40-0.18-0.26
Cash from Operating Activities-1.90-1.75-1.87-1.66-1.71-1.67
Capital Expenditures-0.01-0.00-0.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.00-0.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.82-1.094.013.740.002.53
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.82-1.094.013.740.002.53
Proceedsfrom Stock Options-0.085.810.000.000.003.54
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.89-1.02-0.00-0.01-0.17
Other Financing Activities Uses-0.000.89-1.02-0.00-0.01-0.17
Cash from Financing Activities1.82-0.202.983.74-0.012.36
Exchange Rate Effect-0.000.02-0.000.01-0.02-0.00
Net Change in Cash-0.09-1.931.102.09-1.740.69
Free Cash Flow-1.91-1.75-1.88-1.66-1.71-1.67

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.90%0.0M1.5M2.53M
2026-10-152.21%0.0M1.5M2.52M
2026-09-304.78%0.1M1.6M2.56M
2026-09-154.74%0.1M1.6M1.06M
2026-08-3166.91%0.5M0.7M1.03M
2026-08-149.43%0.1M0.7M140.48K
2026-07-317.35%0.0M0.6M132.05K
2026-07-158.92%0.0M0.5M128.18K
2026-06-309.62%0.0M0.5M120.98K
2026-06-158.25%0.0M0.5M112.25K
2026-05-2922.02%0.1M0.3M104.98K
2026-05-151.92%0.0M0.3M9.24K
2026-04-300.94%0.0M0.3M8.45K
2026-04-152.35%0.0M0.3M10.79K
2026-03-311.15%0.0M0.2M12.50K
2026-03-135.81%0.0M0.2M12.51K
2026-02-277.09%0.0M0.2M24.25K
2026-02-135.82%0.0M0.2M24.39K
2026-01-305.41%0.0M0.2M24.52K
2026-01-152.90%0.0M0.2M24.08K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-154Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-154/A2026-04-17SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-13SCHEDULE 13GSEC
2026-10-098-KCurrent report2026-10-07SEC
2026-10-058-K/A2026-10-01SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-17425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-178-KCurrent report2026-09-17SEC
2026-09-158-KCurrent report2026-09-11SEC
2026-09-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-01DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-01SEC
2026-08-318-KCurrent report2026-08-28SEC
2026-08-21PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-01SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-13SCHEDULE 13G/ASEC
2026-07-318-KCurrent report2026-07-30SEC
2026-07-088-KCurrent report2026-07-06SEC
2026-07-07424B3SEC
2026-07-06EFFECTEffectiveness filing by commission orderSEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-01S-1/ASEC
2026-07-01S-1/ASEC
2026-06-22S-1General form of registration statement for all companies including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP3.07%
CITADEL ADVISORS LLC1.81%
JANE STREET GROUP, LLC1.64%
Shay Capital LLC1.31%
Virtu Financial LLC1.17%
StoneX Group Inc.0.93%
FNY Investment Advisers, LLC0.90%
LEVEL FOUR ADVISORY SERVICES, LLC0.62%
Ikarian Capital, LLC0.61%
GEODE CAPITAL MANAGEMENT, LLC0.43%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.25%
Fidelity Series Total Market Index Fund0.03%
Blackstone Alternative Multi-Strategy Fund-0.02%

OakChart. AEMD. Cached 15 minutes.

Some panels did not load: insider.